PE38897A1 - Solucion acuosa de interferon alfa - Google Patents

Solucion acuosa de interferon alfa

Info

Publication number
PE38897A1
PE38897A1 PE1996000231A PE00023196A PE38897A1 PE 38897 A1 PE38897 A1 PE 38897A1 PE 1996000231 A PE1996000231 A PE 1996000231A PE 00023196 A PE00023196 A PE 00023196A PE 38897 A1 PE38897 A1 PE 38897A1
Authority
PE
Peru
Prior art keywords
aqueous solution
ifn
alfa interferon
interferon alpha
alfa
Prior art date
Application number
PE1996000231A
Other languages
English (en)
Inventor
Gunter Gross
Sabino Del Terzo
Saran Kandakuri Kumar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE38897A1 publication Critical patent/PE38897A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)

Abstract

CARACTERIZADO PORQUE COMPRENDE: A) 1 000 000 UI A 3 600 000 UI DE INTERFERON ALFA (IFN-O); B) DE 0,01 mg/ml A 0,5 mg/ml DE MONOOLEATO DE POLIOXIETILENO (20) SORBITANO; C) DE 10 mM A 15 mM DE UN TAMPON QUE AJUSTE EL pH EN EL RANGO DE 4,5 A 5,5; D) 10 mg DE ALCOHOL BENCILICO; Y E) AGENTE ISOTONIZANTE; EN DONDE: (A) ES: 1) INTERFERON ALFA 2a (IFN-OA) O 2) INTERFERON ALFA 2a PEGUILADO (PEG-INF-OA); (C) ES ACETATO DE AMONIO O LACTATO DE SODIO; Y (E) ES NaCl, MANITOL O GLICERINA, ENTRE OTROS, EN UNA CANTIDAD SUFICIENTE PARA DAR UNA SOLUCION ISOTONICA, DE pH 5 � 0,1. ESTA SOLUCION PERMITE UNA MEJOR ESTABILIDAD AL ALMACENAMIENTO
PE1996000231A 1995-04-06 1996-04-01 Solucion acuosa de interferon alfa PE38897A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
PE38897A1 true PE38897A1 (es) 1997-10-04

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000231A PE38897A1 (es) 1995-04-06 1996-04-01 Solucion acuosa de interferon alfa

Country Status (32)

Country Link
US (1) US5762923A (es)
EP (1) EP0736303B1 (es)
JP (1) JP2758154B2 (es)
KR (1) KR100212346B1 (es)
CN (1) CN1066065C (es)
AR (1) AR002932A1 (es)
AT (1) ATE183650T1 (es)
AU (1) AU685356B2 (es)
BR (1) BR9601276A (es)
CA (1) CA2172664C (es)
CO (1) CO4750807A1 (es)
CY (1) CY2194B1 (es)
CZ (1) CZ287626B6 (es)
DE (1) DE69603894T2 (es)
DK (1) DK0736303T3 (es)
ES (1) ES2136910T3 (es)
GR (1) GR3031775T3 (es)
HK (1) HK1012232A1 (es)
HU (1) HU227643B1 (es)
IL (1) IL117752A (es)
MA (1) MA23838A1 (es)
MY (1) MY113594A (es)
NO (1) NO316801B1 (es)
NZ (1) NZ286300A (es)
PE (1) PE38897A1 (es)
PL (1) PL183873B1 (es)
RU (1) RU2113845C1 (es)
SA (1) SA96160728B1 (es)
SG (1) SG52806A1 (es)
TR (1) TR199600287A2 (es)
TW (1) TW426523B (es)
ZA (1) ZA962553B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
EP1066059B1 (en) * 1998-03-26 2005-06-15 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
AU3473999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Injectable igf-formulations containing succinate as buffering agent
EP1213029A1 (en) 1998-05-15 2002-06-12 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
IL139786A0 (en) * 1998-06-08 2002-02-10 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
KR20010083126A (ko) † 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
JP2002532556A (ja) * 1998-12-22 2002-10-02 シェリング・コーポレーション Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
CA2303992A1 (en) 1999-04-08 2000-10-08 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
PL209928B1 (pl) 2000-11-07 2011-11-30 Novartis Vaccines & Diagnostic Kompozycja farmaceutyczna zawierająca biologicznie aktywny IFN-β i mannitol, wstępnie napełniona strzykawka zawierająca tę kompozycję oraz sposób wytwarzania preparatu IFN-β
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1506786B1 (en) 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
BRPI0409532B8 (pt) 2003-04-02 2021-05-25 Ares Trading Sa composição farmacêutica líquida, artigo de fabricação, método de fabricação de composição farmacêutica e método de fabricação de artigo de fabricação
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EP1748788A1 (en) 2004-05-17 2007-02-07 Ares Trading S.A. Hydrogel interferon formulations
EP1750751B1 (en) 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
MXPA06014079A (es) * 2004-06-01 2007-02-15 Ares Trading Sa Metodo para estabilizar proteinas.
BRPI0513332A (pt) 2004-08-12 2008-05-06 Schering Corp formulação de interferon peguilado estável
US20080193997A1 (en) 2004-08-24 2008-08-14 Kenji Kangawa Liquid Preparation of Physiologically Active Peptide
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
EP1916997B1 (en) * 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
PL2196475T3 (pl) * 2007-09-04 2012-10-31 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN101878043A (zh) 2007-12-20 2010-11-03 默克雪兰诺有限公司 PEG-干扰素-β制剂
CN102123737B (zh) 2008-06-13 2014-01-01 西马生物医学计划公司 用于生物活性化合物施用的轭合物
EP2344201A1 (en) * 2008-09-17 2011-07-20 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3200767A1 (en) * 2014-09-23 2017-08-09 F.Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
WO1990005535A1 (en) * 1988-11-14 1990-05-31 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
IL117752A (en) 2000-11-21
DK0736303T3 (da) 2000-01-10
GR3031775T3 (en) 2000-02-29
NO316801B1 (no) 2004-05-18
MY113594A (en) 2002-04-30
CO4750807A1 (es) 1999-03-31
HUP9600857A2 (en) 1997-08-28
EP0736303A3 (en) 1997-02-26
CN1141808A (zh) 1997-02-05
DE69603894T2 (de) 2000-04-20
NZ286300A (en) 1997-05-26
SG52806A1 (en) 1998-09-28
NO961322L (no) 1996-10-07
ZA962553B (en) 1996-10-07
KR100212346B1 (ko) 1999-08-02
PL313655A1 (en) 1996-10-14
US5762923A (en) 1998-06-09
PL183873B1 (pl) 2002-07-31
ES2136910T3 (es) 1999-12-01
JPH08283176A (ja) 1996-10-29
DE69603894D1 (de) 1999-09-30
EP0736303B1 (en) 1999-08-25
MA23838A1 (fr) 1996-12-31
HK1012232A1 (en) 1999-07-30
CA2172664A1 (en) 1996-10-07
CZ99496A3 (en) 1996-10-16
HU227643B1 (en) 2011-10-28
SA96160728B1 (ar) 2005-05-04
AR002932A1 (es) 1998-05-27
CA2172664C (en) 2000-10-03
HU9600857D0 (en) 1996-05-28
IL117752A0 (en) 1996-08-04
KR960037063A (ko) 1996-11-19
ATE183650T1 (de) 1999-09-15
CZ287626B6 (en) 2001-01-17
RU2113845C1 (ru) 1998-06-27
TR199600287A2 (tr) 1997-03-21
CN1066065C (zh) 2001-05-23
NO961322D0 (no) 1996-04-01
EP0736303A2 (en) 1996-10-09
AU5044696A (en) 1996-10-17
JP2758154B2 (ja) 1998-05-28
BR9601276A (pt) 1998-01-13
AU685356B2 (en) 1998-01-15
HUP9600857A3 (en) 1998-01-28
CY2194B1 (en) 2002-11-08
TW426523B (en) 2001-03-21

Similar Documents

Publication Publication Date Title
PE38897A1 (es) Solucion acuosa de interferon alfa
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
ES2148568T3 (es) Formulaciones de disoluciones acuosas estables de interferon alfa.
ES2097546T3 (es) Preparaciones cosmeticas desodorantes que contienen esteres di- o trigliceridos.
ATE88352T1 (de) Humanes relaxinpraeparat.
CO5700797A2 (es) Composicion de farmaco conjugado
UA41937C2 (uk) Стабільна місцеводіюча ретиноідна композиція
ES2177323T3 (es) Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
IT1258781B (it) Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
ATE257389T1 (de) Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
AR044147A1 (es) Formulaciones liquidas de interferon estabilizadas y libres de hsa
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
ATE94396T1 (de) N-acetylneuraminsaeure enthaltende expektorantien.
ATE355850T1 (de) Lyophilisierte hgf-zubereitungen
MX9305354A (es) Detergente liquido o en forma de gel para el lavado de vajilla que contiene alquil etoxi carboxilato, iones divalentes y alquilpolietoxipolicarboxilato.
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
ES2060248T3 (es) Nebulizador bombeable, acuoso, hidrofilo, que contiene nitroglicerina.
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
AR247804A1 (es) Composicion biocida sinergica y metodo para proteger con la misma composiciones industriales
ES2051827T3 (es) Una composicion farmaceutica que contiene aceite de ricino polietoxilado.
PE20030303A1 (es) FORMULACIONES DE INTERFERON ß HUMANO
ES2164724T3 (es) Uso de una enzima para preparar un agente para el tratamiento y/o la profilaxis de la coccidiosis.
BR9812385A (pt) Formulações parasiticidas
MX9203188A (es) Composicion de barra con cloruro de sodio y alcohol estearilico.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term